Epha2 and EGFR: Friends in Life, Partners in Crime

Total Page:16

File Type:pdf, Size:1020Kb

Epha2 and EGFR: Friends in Life, Partners in Crime cancers Review EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents? Mario Cioce 1,* and Vito Michele Fazio 1,2,3,* 1 Laboratory of Molecular Medicine and Biotechnology, Department of Medicine, University Campus Bio-Medico of Rome, 00128 Rome, Italy 2 Laboratory of Oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy 3 Institute of Translational Pharmacology, National Research Council of Italy (CNR), 00133 Rome, Italy * Correspondence: [email protected] (M.C.); [email protected] (V.M.F.) Simple Summary: The Ephrin receptors and their ligands play important roles in organ formation and tissue repair, by orchestrating complex programs of cell adhesion and repulsion, however, this same system plays a role in cancer development In fact, EphA2 levels are higher in tumors vs normal tissue and further increased upon treatment, in vivo and in vitro. Changes in the molecular status of EphA2, of its subcellular localization, the absence of ligand and signals derived from the tumor context unleash the oncogenic role of EphA2 and its broad ability to promote resistance to radiotherapy, chemotherapy and targeted agents, including inhibitors of Epidermal-Growth-Factor- Receptor (EGFR). High levels of EphA2 may reduce response to cetuximab even in RAS wt CRC patients. In this work, we aim to review the current knowledge of the EphA2 function which is crucial for achieving a more effective therapeutic management of tumors resistant to EGFR inhibitors and to many other agents. Abstract: The Eph receptors represent the largest group among Receptor Tyrosine kinase (RTK) Citation: Cioce, M.; Fazio, V.M. families. The Eph/ephrin signaling axis plays center stage during development, and the deep EphA2 and EGFR: Friends in Life, perturbation of signaling consequent to its dysregulation in cancer reveals the multiplicity and Partners in Crime. Can EphA2 Be a complexity underlying its function. In the last decades, they have emerged as key players in solid Predictive Biomarker of Response to tumors, including colorectal cancer (CRC); however, what causes EphA2 to switch between tumor- Anti-EGFR Agents? Cancers 2021, 13, suppressive and tumor-promoting function is still an active theater of investigation. This review 700. https://doi.org/10.3390/ summarizes the recent advances in understanding EphA2 function in cancer, with detail on the cancers13040700 molecular determinants of the oncogene-tumor suppressor switch function of EphA2. We describe tumor context-specific examples of EphA2 signaling and the emerging role EphA2 plays in supporting Academic Editor: Roberta Alfieri Received: 10 January 2021 cancer—stem—cell-like populations and overcoming therapy-induced stress. In such a frame, we Accepted: 4 February 2021 detail the interaction of the EphA2 and EGFR pathway in solid tumors, including colorectal cancer. Published: 9 February 2021 We discuss the contribution of the EphA2 oncogenic signaling to the resistance to EGFR blocking agents, including cetuximab and TKIs. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Keywords: EphA2; EGFR; TKI; ephrins; CRC; CSCs; drug resistance; cetuximab; intra-tumor hetero- published maps and institutional affil- geneity; inter-tumor heterogeneity iations. 1. Introduction Copyright: © 2021 by the authors. 1.1. General Structure of Eph Receptors and Ephrin Ligands Licensee MDPI, Basel, Switzerland. The EphA2 receptor belongs to the Eph (erythropoietin-producing human hepatocel- This article is an open access article lular) superfamily, the largest among tyrosine kinase receptor families [1]. Eph receptors distributed under the terms and are classified into Eph-A and Eph-B subfamilies depending on their sequence homologies conditions of the Creative Commons and binding affinity for their cognate ephrin ligands. Although Eph receptors preferentially Attribution (CC BY) license (https:// bind ligands of the same class, cross-binding has been described [for a review, [2–4] (Figure creativecommons.org/licenses/by/ 1). All Eph receptors contain an extracellular region, with a conserved N-terminal globular 4.0/). Cancers 2021, 13, 700. https://doi.org/10.3390/cancers13040700 https://www.mdpi.com/journal/cancers Cancers 2021, 13, x 2 of 24 tors are classified into Eph-A and Eph-B subfamilies depending on their sequence homol- Cancers 2021, 13, 700 ogies and binding affinity for their cognate ephrin ligands. Although Eph receptors pref-2 of 23 erentially bind ligands of the same class, cross-binding has been described [for a review, [2–4] (Figure 1). All Eph receptors contain an extracellular region, with a conserved N- terminal globular ligand-binding domain (LBD), a cysteine-rich domain which comprises a Sushiligand-binding and an epidermal domain growth (LBD), factor a cysteine-rich (EGF)-like domain domain which and two comprises fibronectin a Sushi type and-III an epidermal growth factor (EGF)-like domain and two fibronectin type-III repeats (FN1 and repeats (FN1 and FN2). The intracellular region contains a juxtamembrane region (JM), a FN2). The intracellular region contains a juxtamembrane region (JM), a tyrosine kinase tyrosine kinase domain, a sterile alpha motif (SAM) domain, and a PDZ (Post-synaptic domain, a sterile alpha motif (SAM) domain, and a PDZ (Post-synaptic density protein-95, density protein-95, Drosophila disc large tumor suppressor (Dlg), Zona occludens-1) do- Drosophila disc large tumor suppressor (Dlg), Zona occludens-1) domain-binding motif main-binding motif that are responsible for the interaction with effector molecules. The that are responsible for the interaction with effector molecules. The receptor homo- and receptor homo- and hetero-oligomerization involves the extracellular domains (LBD and hetero-oligomerization involves the extracellular domains (LBD and cys-rich domain) [5,6]. cys-rich domain) [5,6]. The SAM domain is involved in receptor-receptor interactions, The SAM domain is involved in receptor-receptor interactions, possibly aiding homo- or possibly aiding homo- or hetero-oligomerization. The ectodomain and the intracellular hetero-oligomerization. The ectodomain and the intracellular domain are linked by a domain are linked by a transmembrane helix (TM) [for reviews, [2,3] (Figure 1). Ephrins transmembrane helix (TM) [for reviews, [2,3] (Figure1). Ephrins ligands are divided into ligands are divided into ephrin-A and ephrin-B subclasses [5,7]. Ephrin-A proteins (A1– ephrin-A and ephrin-B subclasses [5,7]. Ephrin-A proteins (A1–A6) are anchored to the A6)extracellular are anchored cell to membranethe extracellular via a glycosylcell membrane phosphatidylinositol via a glycosyl (GPI)phosphatidylinositol linkage that could (GPI)be linkage released that to activatecould beEphA released receptors to activate at distance EphA receptors [8]. Ephrin-B at distance members [8]. Ephrin (B1–B3)-B are memberstransmembrane (B1–B3) are proteins transmembrane containing protein a cytoplasmics containing domain a cytoplasmic with several domain conserved with tyrosinesev- eralresidues conserved and tyrosine a terminal residues PDZ-binding and a terminal motif allowing PDZ-binding the interaction motif allowing with proteins the interac- involved tionin with cytoskeleton proteins organizationinvolved in cytoskeleton and cell adhesion organization (Figure 1and). Thus, cell Eph-ephrinadhesion (Figure signaling 1). is Thus,transduced Eph-ephrin either signaling directly is (intransduced the case either of ephrin-Bs) directly or(in by the interaction case of ephrin with-Bs) intracellular or by interactionproteins with (like intracellular Fyn) or other proteins transmembrane (like Fyn) proteinsor other transmembrane (like the neurotrophin proteins receptor (like the p75) neurotrophin(as for ephrin-As receptor [9 ]p75) (Figure (as for1). ephrin-As [9] (Figure 1). FigureFigure 1. The 1. structureThe structure of Eph of receptors Eph receptors and their and ligands their ligands is shown. isshown. Eph receptors Eph receptors are consisting are consisting of an extracellular of an extracellular struc- turestructure consisting consisting of an ephrin of an ephrinbinding binding domain domain connected connected to two to fibronectin two fibronectin type- type-IIIIII repeats repeats by a bycysteine a cysteine-rich-rich EGF EGF-like-like motif.motif. The Thejuxtamembrane juxtamembrane region region connects connects the theextracellular extracellular portion portion of the of thereceptor receptor to the to theintracellular intracellular kinase kinase domain domain that that is linked to a sterile alpha motif (SAM) domain and PDZ-binding motif. Eph ligands (ephrin-A/B) are composed of a GPI- is linked to a sterile alpha motif (SAM) domain and PDZ-binding motif. Eph ligands (ephrin-A/B) are composed of a anchored receptor binding domain in the case of the ephrin-A type and a receptor-binding domain connected by a jux- GPI-anchored receptor binding domain in the case of the ephrin-A type and a receptor-binding domain connected by a tamembrane domain to a cytoplasmic domain and a PDZ interaction motif, in the case of ephrin-B. Eph-Ephrin signaling is transducedjuxtamembrane either domain directly to (in a cytoplasmicthe case of ephrin domain-Bs) and or a by PDZ interaction interaction with motif, Fyn in (as the has case been of ephrin-B.observed Eph-Ephrinwith ephrin signaling-As). Ligandis transduced binding likely either initiates directly clustering, (in the
Recommended publications
  • Chemoresistance in Human Ovarian Cancer: the Role of Apoptotic
    Reproductive Biology and Endocrinology BioMed Central Review Open Access Chemoresistance in human ovarian cancer: the role of apoptotic regulators Michael Fraser1, Brendan Leung1, Arezu Jahani-Asl1, Xiaojuan Yan1, Winston E Thompson2 and Benjamin K Tsang*1 Address: 1Department of Obstetrics & Gynecology and Cellular & Molecular Medicine, University of Ottawa, Ottawa Health Research Institute, Ottawa, Canada K1Y 4E9, Canada and 2Department of Obstetrics & Gynecology and Cooperative Reproductive Science Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA Email: Michael Fraser - [email protected]; Brendan Leung - [email protected]; Arezu Jahani-Asl - [email protected]; Xiaojuan Yan - [email protected]; Winston E Thompson - [email protected]; Benjamin K Tsang* - [email protected] * Corresponding author Published: 07 October 2003 Received: 26 June 2003 Accepted: 07 October 2003 Reproductive Biology and Endocrinology 2003, 1:66 This article is available from: http://www.RBEj.com/content/1/1/66 © 2003 Fraser et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Abstract Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Recent evidence suggests that deregulation of key pro- and anti-apoptotic pathways is a key factor in the onset and maintenance of chemoresistance. Furthermore, the discovery of novel interactions between these pathways suggests that chemoresistance may be multi-factorial. Ultimately, the decision of the cancer cell to live or die in response to a chemotherapeutic agent is a consequence of the overall apoptotic capacity of that cell.
    [Show full text]
  • Ephrin-A1 Expression Contributes to the Malignant Characteristics of A
    843 HEPATOBILIARY DISEASE Ephrin-A1 expression contributes to the malignant Gut: first published as 10.1136/gut.2004.049486 on 11 May 2005. Downloaded from characteristics of a-fetoprotein producing hepatocellular carcinoma H Iida, M Honda, H F Kawai, T Yamashita, Y Shirota, B-C Wang, H Miao, S Kaneko ............................................................................................................................... Gut 2005;54:843–851. doi: 10.1136/gut.2004.049486 Background and aims: a-Fetoprotein (AFP), a tumour marker for hepatocellular carcinoma (HCC), is associated with poor prognosis. Using cDNA microarray analysis, we previously found that ephrin-A1, an angiogenic factor, is the most differentially overexpressed gene in AFP producing hepatoma cell lines. In the present study, we investigated the significance of ephrin-A1 expression in HCC. See end of article for Methods: We examined ephrin-A1 expression and its effect on cell proliferation and gene expression in authors’ affiliations five AFP producing hepatoma cell lines, three AFP negative hepatoma cell lines, and 20 human HCC ....................... specimens. Correspondence to: Results: Ephrin-A1 expression levels were lowest in normal liver tissue, elevated in cirrhotic tissue, and Dr S Kaneko, Department further elevated in HCC specimens. Ephrin-A1 expression was strongly correlated with AFP expression of Cancer Gene (r = 0.866). We showed that ephrin-A1 induced expression of AFP. This finding implicates ephrin-A1 in Regulation, Kanazawa University Graduate the mechanism of AFP induction in HCC. Ephrin-A1 promoted the proliferation of ephrin-A1 School of Medical Science, underexpressing HLE cells, and an ephrin-A1 antisense oligonucleotide inhibited the proliferation of 13-1 Takara-Machi, ephrin-A1 overexpressing Huh7 cells.
    [Show full text]
  • Itk Tyrosine Kinase Substrate Docking Is Mediated by a Nonclassical SH2 Domain Surface of PLC␥1
    Itk tyrosine kinase substrate docking is mediated by a nonclassical SH2 domain surface of PLC␥1 Lie Min, Raji E. Joseph, D. Bruce Fulton, and Amy H. Andreotti1 Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA 50011 Edited by Susan S. Taylor, University of California at San Diego, La Jolla, CA, and approved October 20, 2009 (received for review October 1, 2009) Interleukin-2 tyrosine kinase (Itk) is a Tec family tyrosine kinase that We have previously shown that the PLC␥1 SH2C domain mediates signaling processes after T cell receptor engagement. Acti- (spanning residues 659–756 within full-length PLC␥1) binds di- vation of Itk requires recruitment to the membrane via its pleckstrin rectly to the Itk kinase domain and is required for efficient homology domain, phosphorylation of Itk by the Src kinase, Lck, and phosphorylation of Y783 by Itk (26). Fragments of PLC␥1 that binding of Itk to the SLP-76/LAT adapter complex. After activation, Itk contain Y783 but not the SH2C domain are not efficiently phos- phosphorylates and activates phospholipase C-␥1 (PLC-␥1), leading to phorylated by Itk. Moreover, phosphorylation of PLC␥1 substrate production of two second messengers, DAG and IP3. We have previ- fragments that contain both SH2C and Y783 (spanning 659–789, ously shown that phosphorylation of PLC-␥1 by Itk requires a direct, hereafter referred to as PLC␥1 SH2C-linker) can be inhibited by phosphotyrosine-independent interaction between the Src homol- titration with isolated PLC␥1 SH2C domain (26). The excess, free ogy 2 (SH2) domain of PLC-␥1 and the kinase domain of Itk.
    [Show full text]
  • Detection of Pro Angiogenic and Inflammatory Biomarkers in Patients With
    www.nature.com/scientificreports OPEN Detection of pro angiogenic and infammatory biomarkers in patients with CKD Diana Jalal1,2,3*, Bridget Sanford4, Brandon Renner5, Patrick Ten Eyck6, Jennifer Laskowski5, James Cooper5, Mingyao Sun1, Yousef Zakharia7, Douglas Spitz7,9, Ayotunde Dokun8, Massimo Attanasio1, Kenneth Jones10 & Joshua M. Thurman5 Cardiovascular disease (CVD) is the most common cause of death in patients with native and post-transplant chronic kidney disease (CKD). To identify new biomarkers of vascular injury and infammation, we analyzed the proteome of plasma and circulating extracellular vesicles (EVs) in native and post-transplant CKD patients utilizing an aptamer-based assay. Proteins of angiogenesis were signifcantly higher in native and post-transplant CKD patients versus healthy controls. Ingenuity pathway analysis (IPA) indicated Ephrin receptor signaling, serine biosynthesis, and transforming growth factor-β as the top pathways activated in both CKD groups. Pro-infammatory proteins were signifcantly higher only in the EVs of native CKD patients. IPA indicated acute phase response signaling, insulin-like growth factor-1, tumor necrosis factor-α, and interleukin-6 pathway activation. These data indicate that pathways of angiogenesis and infammation are activated in CKD patients’ plasma and EVs, respectively. The pathways common in both native and post-transplant CKD may signal similar mechanisms of CVD. Approximately one in 10 individuals has chronic kidney disease (CKD) rendering CKD one of the most common diseases worldwide1. CKD is associated with a high burden of morbidity in the form of end stage kidney disease (ESKD) requiring dialysis or transplantation 2. Furthermore, patients with CKD are at signifcantly increased risk of death from cardiovascular disease (CVD)3,4.
    [Show full text]
  • Novel Protein-Tyrosine Kinase Gene (Hck) Preferentially Expressed in Cells of Hematopoietic Origin STEVEN F
    MOLECULAR AND CELLULAR BIOLOGY, June 1987, p. 2276-2285 Vol. 7, No. 6 0270-7306/87/062276-10$02.00/0 Copyright © 1987, American Society for Microbiology Novel Protein-Tyrosine Kinase Gene (hck) Preferentially Expressed in Cells of Hematopoietic Origin STEVEN F. ZIEGLER,"12 JAMEY D. MARTH,"', DAVID B. LEWIS,4 AND ROGER M. PERLMUTTER' 2,5* Howard Hughes Medical Institute' and the Departments ofBiochemistry,2 Medicine,s Pediatrics,4 and Pharmacology,3 University of Washington School of Medicine, Seattle, Washington 98195 Received 16 December 1986/Accepted 18 March 1987 Protein-tyrosine kinases are implicated in the control of cell growth by virtue of their frequent appearance as products of retroviral oncogenes and as components of growth factor receptors. Here we report the characterization of a novel human protein-tyrosine kinase gene (hck) that is primarily expressed in hematopoietic cells, particularly granulocytes. The hck gene encodes a 505-residue polypeptide that is closely related to pp56kk, a lymphocyte-specific protein-tyrosine kinase. The exon breakpoints of the hck gene, partially defined by using murine genomic clones, demonstrate that hck is a member of the src gene family and has been subjected to strong selection pressure during mammalian evolution. High-level expression of hck transcripts in granulocytes is especially provocative since these cells are terminally differentiated and typically survive in vivo for only a few hours. Thus the hck gene, like other members of the src gene family, appears to function primarily in cells with little growth potential. Specific phosphorylation of proteins on tyrosine residues line Ml induces monocytoid differentiation (18), presumably was first detected in lysates of cells infected with acutely as a result of activation of endogenous pp60csrc (7).
    [Show full text]
  • Mtorc1-Independent Autophagy Regulates Receptor Tyrosine Kinase Phosphorylation in Colorectal Cancer Cells Via an Mtorc2-Mediated Mechanism
    Cell Death and Differentiation (2017) 24, 1045–1062 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/17 www.nature.com/cdd mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism Aikaterini Lampada1,2, James O’Prey3, Gyorgy Szabadkai4, Kevin M Ryan3, Daniel Hochhauser*,2,5 and Paolo Salomoni*,1,5 The intracellular autophagic degradative pathway can have a tumour suppressive or tumour-promoting role depending on the stage of tumour development. Upon starvation or targeting of oncogenic receptor tyrosine kinases (RTKs), autophagy is activated owing to the inhibition of PI3K/AKT/mTORC1 signalling pathway and promotes survival, suggesting that autophagy is a relevant therapeutic target in these settings. However, the role of autophagy in cancer cells where the PI3K/AKT/mTORC1 pathway is constitutively active remains partially understood. Here we report a role for mTORC1-independent basal autophagy in regulation of RTK activation and cell migration in colorectal cancer (CRC) cells. PI3K and RAS-mutant CRC cells display basal autophagy levels despite constitutive mTORC1 signalling, but fail to increase autophagic flux upon RTK inhibition. Inhibition of basal autophagy via knockdown of ATG7 or ATG5 leads to decreased phosphorylation of several RTKs, in particular c-MET. Internalised c-MET colocalised with LAMP1-negative, LC3-positive vesicles. Finally, autophagy regulates c-MET phosphorylation via an mTORC2- dependent
    [Show full text]
  • The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2
    Khemlina et al. Molecular Cancer (2017) 16:149 DOI 10.1186/s12943-017-0712-x REVIEW Open Access The biology of Hepatocellular carcinoma: implications for genomic and immune therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2 Abstract Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading cause of cancer-related death worldwide. It is highly refractory to most systemic therapies. Recently, significant progress has been made in uncovering genomic alterations in HCC, including potentially targetable aberrations. The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes. PTEN loss at the protein level is also frequent. Genomic portfolios stratify by risk factors as follows: (i) CTNNB1 with alcoholic cirrhosis; and (ii) TP53 with hepatitis B virus-induced cirrhosis. Activating mutations in CTNNB1 and inactivating mutations in AXIN1 both activate WNT signaling. Alterations in this pathway, as well as in TP53 and the cell cycle machinery, and in the PI3K/Akt/mTor axis (the latter activated in the presence of PTEN loss), as well as aberrant angiogenesis and epigenetic anomalies, appear to be major events in HCC. Many of these abnormalities may be pharmacologically tractable. Immunotherapy with checkpoint inhibitors is also emerging as an important treatment option. Indeed, 82% of patients express PD-L1 (immunohistochemistry) and response rates to anti-PD-1 treatment are about 19%, and include about 5% complete remissions as well as durable benefit in some patients. Biomarker-matched trials are still limited in this disease, and many of the genomic alterations in HCC remain challenging to target.
    [Show full text]
  • Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum
    The Journal of Neuroscience, June 15, 1999, 19(12):4962–4971 Ephrin-A Binding and EphA Receptor Expression Delineate the Matrix Compartment of the Striatum L. Scott Janis, Robert M. Cassidy, and Lawrence F. Kromer Department of Cell Biology and Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007 The striatum integrates limbic and neocortical inputs to regulate matrix neurons. In situ hybridization for EphA RTKs reveals that sensorimotor and psychomotor behaviors. This function is de- the two different ligand binding patterns strictly match pendent on the segregation of striatal projection neurons into the mRNA expression patterns of EphA4 and EphA7. anatomical and functional components, such as the striosome Ligand–receptor binding assays indicate that ephrin-A1 and and matrix compartments. In the present study the association ephrin-A4 selectively bind EphA4 but not EphA7 in the lysates of ephrin-A cell surface ligands and EphA receptor tyrosine of striatal tissue. Conversely, ephrin-A2, ephrin-A3, and kinases (RTKs) with the organization of these compartments ephrin-A5 bind EphA7 but not EphA4. These observations im- was determined in postnatal rats. Ephrin-A1 and ephrin-A4 plicate selective interactions between ephrin-A molecules and selectively bind to EphA receptors on neurons restricted to the EphA RTKs as potential mechanisms for regulating the com- matrix compartment. Binding is absent from the striosomes, partmental organization of the striatum. which were identified by m-opioid
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • The Receptor Tyrosine Kinase Epha2 Promotes Mammary Adenocarcinoma Tumorigenesis and Metastatic Progression in Mice by Amplifying Erbb2 Signaling
    The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling Dana M. Brantley-Sieders, … , Rebecca S. Muraoka-Cook, Jin Chen J Clin Invest. 2008;118(1):64-78. https://doi.org/10.1172/JCI33154. Research Article Oncology Overexpression of the receptor tyrosine kinase EPH receptor A2 (EphA2) is commonly observed in aggressive breast cancer and correlates with a poor prognosis. However, while EphA2 has been reported to enhance tumorigenesis, proliferation, and MAPK activation in several model systems, other studies suggest that EphA2 activation diminishes these processes and inhibits the activity of MAPK upon ligand stimulation. In this study, we eliminated EphA2 expression in 2 transgenic mouse models of mammary carcinoma. EphA2 deficiency impaired tumor initiation and metastatic progression in mice overexpressing ErbB2 (also known as Neu) in the mammary epithelium (MMTV-Neu mice), but not in mice overexpressing the polyomavirus middle T antigen in mammary epithelium (MMTV–PyV-mT mice). Histologic and ex vivo analyses of MMTV-Neu mouse mammary epithelium indicated that EphA2 enhanced tumor proliferation and motility. Biochemical analyses revealed that EphA2 formed a complex with ErbB2 in human and murine breast carcinoma cells, resulting in enhanced activation of Ras-MAPK signaling and RhoA GTPase. Additionally, MMTV-Neu, but not MMTV–PyV-mT, tumors were sensitive to therapeutic inhibition of EphA2. These data suggest that EphA2 cooperates with ErbB2 to promote tumor progression in mice and may provide a novel therapeutic target for ErbB2-dependent tumors in humans. Moreover, EphA2 function in tumor progression appeared to depend on oncogene context, an important consideration for the application of therapies targeting EphA2.
    [Show full text]
  • Ephrin-A2 Reverse Signaling Negatively Regulates Neural Progenitor Proliferation and Neurogenesis
    Downloaded from genesdev.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Ephrin-A2 reverse signaling negatively regulates neural progenitor proliferation and neurogenesis Johan Holmberg,1 Annika Armulik,1 Kirsten-André Senti,1,3 Karin Edoff,1 Kirsty Spalding,1 Stefan Momma,1 Rob Cassidy,1 John G. Flanagan,2 and Jonas Frisén1,4 1Department of Cell and Molecular Biology, Medical Nobel Institute, Karolinska Institute, SE-171 77 Stockholm, Sweden; 2Department of Cell Biology and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115, USA The number of cells in an organ is regulated by mitogens and trophic factors that impinge on intrinsic determinants of proliferation and apoptosis. We here report the identification of an additional mechanism to control cell number in the brain: EphA7 induces ephrin-A2 reverse signaling, which negatively regulates neural progenitor cell proliferation. Cells in the neural stem cell niche in the adult brain proliferate more and have a shorter cell cycle in mice lacking ephrin-A2. The increased progenitor proliferation is accompanied by a higher number of cells in the olfactory bulb. Disrupting the interaction between ephrin-A2 and EphA7 in the adult brain of wild-type mice disinhibits proliferation and results in increased neurogenesis. The identification of ephrin-A2 and EphA7 as negative regulators of progenitor cell proliferation reveals a novel mechanism to control cell numbers in the brain. [Keywords: SVZ; adult; neuronal progenitors; proliferation; ephrins; reverse signaling] Supplemental material is available at http://www.genesdev.org. Received October 1, 2004; revised version accepted December 16, 2004. Most neurons are generated before birth and neurogen- ing proliferation and neurogenesis within the stem cell esis in the adult brain is limited to a few regions.
    [Show full text]
  • Inhibition of Metastasis by HEXIM1 Through Effects on Cell Invasion and Angiogenesis
    Oncogene (2013) 32, 3829–3839 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis W Ketchart1, KM Smith2, T Krupka3, BM Wittmann1,7,YHu1, PA Rayman4, YQ Doughman1, JM Albert5, X Bai6, JH Finke4,YXu2, AA Exner3 and MM Montano1 We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF-1a protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory pro- angiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.
    [Show full text]